Michel P Coleman
Overview
Explore the profile of Michel P Coleman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
141
Citations
8428
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Niksic M, Minicozzi P, Weir H, Zimmerman H, Schymura M, Rees J, et al.
Cancer Commun (Lond)
. 2022 Nov;
43(1):87-99.
PMID: 36353792
Background: Survival from pancreatic cancer is low worldwide. In the US, the 5-year relative survival has been slightly higher for women, whites and younger patients than for their counterparts, and...
12.
Girardi F, Di Carlo V, Stiller C, Gatta G, Woods R, Visser O, et al.
Neuro Oncol
. 2022 Oct;
25(3):593-606.
PMID: 36215122
Introduction: Tumors of the central nervous system are among the leading causes of cancer-related death in children. Population-based cancer survival reflects the overall effectiveness of a health care system in...
13.
Montel L, Ssenyonga N, Coleman M, Allemani C
Int J Equity Health
. 2022 Sep;
21(1):139.
PMID: 36138460
The human right to health is a critical legal tool to achieve health justice, and universal health coverage is included among the Sustainable Development Goals. However, the content and meaning...
14.
Nemati S, Saeedi E, Lotfi F, Nahvijou A, Mohebbi E, Ravankhah Z, et al.
Int J Cancer
. 2022 Jul;
151(12):2128-2135.
PMID: 35869869
Cancer survival is a key indicator for the national cancer control programs. However, survival data in the East Mediterranean region (EMR) are limited. We designed a national cancer survival study...
15.
Niksic M, Matz M, Valkov M, Marcos-Gragera R, Stiller C, Rosso S, et al.
Cancer Epidemiol
. 2022 Jul;
80:102196.
PMID: 35841761
Background: Ductal adenocarcinomas and neuroendocrine tumours are the two main morphological sub-types of pancreatic cancer. Using data from CONCORD-3, we examined whether the distribution of morphological sub-types could help explain...
16.
Matz M, Gamkrelidze A, Mebonia N, Kereselidze M, Kazanjan K, Zhizhilashvili S, et al.
Cancer Epidemiol
. 2022 Jun;
79:102190.
PMID: 35696766
Background: Population-based cancer survival is a key metric of the effectiveness of health systems in managing cancer. Data from population-based cancer registries are essential for producing reliable and robust cancer...
17.
Girardi F, Coleman M, Allemani C
Neuro Oncol
. 2022 May;
24(7):1208-1209.
PMID: 35596727
No abstract available.
18.
Matz M, Allemani C, Van Tongeren M, Nafilyan V, Rhodes S, van Veldhoven K, et al.
J Epidemiol Community Health
. 2022 Apr;
76(7):660-666.
PMID: 35470261
Background: Exposure to SARS-CoV-2, subsequent development of COVID-19 and death from COVID-19 may vary by occupation, and the risks may be higher for those categorised as 'essential workers'. Methods: We...
19.
Ssenyonga N, Stiller C, Nakata K, Shalkow J, Redmond S, Bulliard J, et al.
Lancet Child Adolesc Health
. 2022 Apr;
6(6):409-431.
PMID: 35468327
Background: Leukaemias comprise a heterogenous group of haematological malignancies. In CONCORD-3, we analysed data for children (aged 0-14 years) and adults (aged 15-99 years) diagnosed with a haematological malignancy during...
20.
Di Carlo V, Stiller C, Eisemann N, Bordoni A, Matz M, Curado M, et al.
Br J Dermatol
. 2022 Mar;
187(3):364-380.
PMID: 35347700
Background: CONCORD-3 highlighted wide disparities in population-based 5-year net survival for cutaneous melanoma during 2000-2014. Clinical evidence suggests marked international differences in the proportion of lethal acral and nodular subtypes...